Kura Oncology's KOMZIFTI Gains Market Share in AML Treatment — Kura Oncology, Inc.

Event summary

$9.1 million in net product revenue for KOMZIFTI, up 57% from Q1 2026.
KOMZIFTI achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class.
Long-term frontline AML data presented at EHA 2026 support potential for ziftomenib to transform standard of care and a $7 billion TAM.
$519.0 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments.

The big picture

Kura Oncology's strong Q2 2026 results highlight the growing acceptance of KOMZIFTI in the AML treatment landscape. The company's strategic focus on expanding ziftomenib into earlier lines of therapy and combining it with multiple standards of care positions it to capture a significant share of the $7 billion TAM. The emerging potential of darlifarnib as a precision combination platform across solid tumors further strengthens Kura's long-term value proposition in the biopharmaceutical industry.

What we're watching

Market Expansion: How Kura Oncology will sustain the momentum of KOMZIFTI's market share growth in AML treatment.
Clinical Development: Whether the ongoing clinical trials for ziftomenib and darlifarnib will meet their anticipated milestones.
Financial Stability: The pace at which Kura Oncology can maintain its cash runway through 2028 with current financial resources.